8:45am ET
Investing
Huge Insider Buying Now at This Insurance Giant and 2 Biotechs
Alumis, Aktis Oncology, and W.R. Berkley saw the most prominent insider buying of the past week. There were a handful of other notable purchases as well.
Companies
/Healthcare
Alumis Inc
$7.16
▲ $0.19 (+2.73%) today
Markets closed · 10:27pm ET
ALMS at a Glance
Valuation
- Market cap
- $926.8M
Profitability
- Revenue (TTM)
- $7.4M
- EPS (TTM)
- $-3.97
Price
- 52-week range
- $4 – $31
- Street target
- $32.12
Earnings
- Next report
- Nov 12, 2026
Headquartered in South San Francisco, CA Fiscal year ends December NASDAQ: ALMS alumis.com
About Alumis
Alumis Inc. is a late-stage biopharmaceutical company developing next-generation targeted therapies for immune-mediated diseases. The company leverages a proprietary data analytics platform and precision approach to develop a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors. Its lead candidate, envudeucitinib (formerly ESK-001), is in late-stage clinical development for systemic immune-mediated disorders including moderate-to-severe plaque psoriasis (NDA submission planned Q4 2026) and systemic lupus erythematosus (Phase 2b). The company is also developing A-005, a CNS-penetrant TYK2 inhibitor initially focused on Parkinson's disease and additional neuroinflammatory and neurodegenerative indications. Alumis generates limited collaboration revenue from a licensing agreement with Kaken Pharmaceutical Co., Ltd. The company merged with ACELYRIN, Inc. in 2025, and is exploring strategic alternatives for its lonigutamab program. Updated
Frequently Asked Questions
What does Alumis do?
Alumis Inc. is a late-stage biopharmaceutical company developing next-generation targeted therapies for immune-mediated diseases. The company leverages a proprietary data analytics platform and precision approach to develop a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors.
What is the ALMS stock price target?
The Wall Street consensus 12-month price target for ALMS is $32.12.